AR065797A1 - Usos y derivados de 1-(2- (2,4- dimetilfenilsulfanil) fenil) piperazina - Google Patents

Usos y derivados de 1-(2- (2,4- dimetilfenilsulfanil) fenil) piperazina

Info

Publication number
AR065797A1
AR065797A1 ARP080101145A ARP080101145A AR065797A1 AR 065797 A1 AR065797 A1 AR 065797A1 AR P080101145 A ARP080101145 A AR P080101145A AR P080101145 A ARP080101145 A AR P080101145A AR 065797 A1 AR065797 A1 AR 065797A1
Authority
AR
Argentina
Prior art keywords
piperazine
phenyl
dimetilfenilsulfanil
derivatives
compound
Prior art date
Application number
ARP080101145A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39564604&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065797(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/DK2007/050075 external-priority patent/WO2007144005A1/en
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR065797A1 publication Critical patent/AR065797A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona el uso de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina en el tratamiento del dolor y de los síntomas residuales en la depresion. Reivindicacion 11: 1-[2-(2,4 dimetilfenilsulfanil)fenil]piperazina y sus sales de adicion de ácidoaceptables para uso farmacéutico (compuesto 1) para utilizar en el tratamiento del dolor o de los síntomas residuales en la depresion. Reivindicacion 12: El compuesto de acuerdo con la reivindicacion 11, donde el compuesto 1 es la sal de adicionde ácido HBr.
ARP080101145A 2007-03-20 2008-03-19 Usos y derivados de 1-(2- (2,4- dimetilfenilsulfanil) fenil) piperazina AR065797A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200700427 2007-03-20
PCT/DK2007/050075 WO2007144005A1 (en) 2006-06-16 2007-06-15 1- [2- (2, 4-dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment

Publications (1)

Publication Number Publication Date
AR065797A1 true AR065797A1 (es) 2009-07-01

Family

ID=39564604

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101145A AR065797A1 (es) 2007-03-20 2008-03-19 Usos y derivados de 1-(2- (2,4- dimetilfenilsulfanil) fenil) piperazina

Country Status (29)

Country Link
US (1) US8664225B2 (es)
EP (1) EP2142193B1 (es)
JP (1) JP5371790B2 (es)
KR (1) KR101459168B1 (es)
CN (2) CN103948597A (es)
AR (1) AR065797A1 (es)
AT (1) ATE495745T1 (es)
AU (1) AU2008228638B2 (es)
BR (1) BRPI0808941A2 (es)
CA (1) CA2684571C (es)
CL (1) CL2008000795A1 (es)
CO (1) CO6220962A2 (es)
CY (1) CY1111183T1 (es)
DE (1) DE602008004643D1 (es)
DK (1) DK2142193T3 (es)
EA (1) EA017058B1 (es)
ES (1) ES2355434T3 (es)
HR (1) HRP20110058T1 (es)
IL (2) IL200956A (es)
MX (1) MX2009009672A (es)
MY (1) MY150448A (es)
NZ (1) NZ579721A (es)
PL (1) PL2142193T3 (es)
PT (1) PT2142193E (es)
RS (1) RS51560B (es)
SI (1) SI2142193T1 (es)
TW (1) TW200848411A (es)
UA (1) UA97392C2 (es)
WO (1) WO2008113359A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52205B2 (sr) * 2006-06-16 2021-05-31 H Lundbeck A/S 1-[2-(2,4-dimetilfenilsulfanil)-fenil]piperazin kao jedinjenje sa kombinovanom aktivnošću ponovnog uzimanja serotonina, 5-ht3 i 5-ht1a, za tretman kognitivnih oštećenja
AU2014200364B2 (en) * 2007-11-13 2015-09-17 H. Lundbeck A/S Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW201033181A (en) * 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
GEP20135938B (en) 2009-04-24 2013-10-10 H Lundbeck As Liquid pharmaceutical formulations of 1-[2-(2,4-dimethylsulfanyl)phenyl]piperazine
CA2769872A1 (en) 2009-08-24 2011-03-03 H. Lundbeck A/S New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
MA34261B1 (fr) * 2010-04-30 2013-05-02 Takeda Pharmaceutcal Company Ltd Comprime a delitage intestinal
TW201212918A (en) 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
CA2885266C (en) 2012-09-19 2020-05-12 Sandoz Ag Novel crystalline form of vortioxetine hydrobromide
WO2015035802A1 (zh) * 2013-09-12 2015-03-19 杭州普晒医药科技有限公司 沃替西汀盐及其晶体、它们的制备方法、药物组合物和用途
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
CA2933733A1 (en) 2013-12-20 2015-06-25 Connie Sanchez Morillo Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
US9822086B2 (en) 2014-01-31 2017-11-21 Egis Gyogyszergyar Zrt. Process for the preparation of vortioxetine salts
CN104059030B (zh) 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
CN105198837B (zh) * 2014-06-09 2018-05-04 上海医药工业研究院 一种沃替西汀氢溴酸盐晶体及其制备方法
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
CN106279066A (zh) * 2015-05-22 2017-01-04 天津药物研究院有限公司 一种氢溴酸沃替西汀晶体的纯化方法
CN106556663B (zh) * 2015-09-30 2018-05-29 成都弘达药业有限公司 一种1-[2-(2,4-二甲基苯基硫烷基)苯基]哌嗪或其盐的检测方法
US10927089B2 (en) 2016-06-16 2021-02-23 Sunshine Lake Pharma Co., Ltd. Diaryl thioether piperazine compounds, preparation methods and uses thereof
SG11201810644TA (en) * 2016-07-01 2018-12-28 H Lundbeck As Vortioxetine dosing regimes for fast onset of antidepressant effect
JP7121751B2 (ja) * 2017-04-25 2022-08-18 ハー・ルンドベック・アクチエゼルスカベット ボルチオキセチンＨＢｒ α型を製造するための方法
KR102026337B1 (ko) 2017-07-07 2019-09-27 영진약품 주식회사 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법
WO2023036820A1 (en) 2021-09-10 2023-03-16 H. Lundbeck A/S Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA76130C2 (en) * 2000-11-20 2006-07-17 Merck Patent Gmbh Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
CA2467118A1 (en) * 2001-12-20 2003-07-03 H. Lundbeck A/S Aryloxyphenyl and arylsulfanylphenyl derivatives
RS52205B2 (sr) * 2006-06-16 2021-05-31 H Lundbeck A/S 1-[2-(2,4-dimetilfenilsulfanil)-fenil]piperazin kao jedinjenje sa kombinovanom aktivnošću ponovnog uzimanja serotonina, 5-ht3 i 5-ht1a, za tretman kognitivnih oštećenja

Also Published As

Publication number Publication date
IL200956A0 (en) 2010-05-17
AU2008228638B2 (en) 2012-09-20
KR101459168B1 (ko) 2014-11-07
CN103948597A (zh) 2014-07-30
DK2142193T3 (da) 2011-03-28
DE602008004643D1 (de) 2011-03-03
IL200956A (en) 2015-05-31
TW200848411A (en) 2008-12-16
BRPI0808941A2 (pt) 2014-08-19
WO2008113359A3 (en) 2008-11-13
US20110009422A1 (en) 2011-01-13
CA2684571C (en) 2012-08-14
RS51560B (en) 2011-06-30
EP2142193A2 (en) 2010-01-13
CL2008000795A1 (es) 2008-09-26
CN101636161A (zh) 2010-01-27
IL238068A0 (en) 2015-05-31
US8664225B2 (en) 2014-03-04
ES2355434T3 (es) 2011-03-25
WO2008113359A2 (en) 2008-09-25
CO6220962A2 (es) 2010-11-19
JP2010521501A (ja) 2010-06-24
AU2008228638A1 (en) 2008-09-25
PT2142193E (pt) 2011-02-02
EA017058B1 (ru) 2012-09-28
EP2142193B1 (en) 2011-01-19
ATE495745T1 (de) 2011-02-15
EA200970870A1 (ru) 2010-04-30
SI2142193T1 (sl) 2011-03-31
MY150448A (en) 2014-01-30
CY1111183T1 (el) 2015-06-11
NZ579721A (en) 2011-07-29
UA97392C2 (ru) 2012-02-10
PL2142193T3 (pl) 2011-04-29
HRP20110058T1 (hr) 2011-03-31
CA2684571A1 (en) 2008-09-25
JP5371790B2 (ja) 2013-12-18
MX2009009672A (es) 2009-12-15
KR20090125251A (ko) 2009-12-04

Similar Documents

Publication Publication Date Title
AR065797A1 (es) Usos y derivados de 1-(2- (2,4- dimetilfenilsulfanil) fenil) piperazina
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
ECSP055853A (es) Nuevos derivados de fluoroglicosidos heterociclicos, productos farmaceuticos que contienen dichos compuestos, y el uso de los mismos
NI201200184A (es) Morfolinopirimidinas y su uso en terapia
CU20110145A7 (es) Derivados de sulfonamida
AR055076A1 (es) Derivados de1,1-dioxido de 1,4-benzotiazepina,procedimiento para prepararlos,composiciones farmaceuticas que los contienen y usos en terapeutica.
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
DOP2009000254A (es) Derivados de piridina
CR11857A (es) Compuestos pirazolicos 436
UY33491A (es) ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?.
UY32351A (es) Compuestos de pirimidinil indol para uso como inhibidores de atr
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
ECSP12012174A (es) Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a
GT200600496A (es) Sales, profarmacos y formulaciones de 1-[5-(4-amino-7-isopropil-7h-pirrolo[2,3-d]piirimidin-5-carbonil)-2-metoxi-feil]-3-(2,4-dicloro-fenil)-urea.
BRPI0924183B8 (pt) inibidores de cdk4/6 quinase, seus usos e sua forma cristalina iii, e formulação farmacêutica
UY31189A1 (es) Compuestos heterocíclicos
CL2011002706A1 (es) Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras.
AR065798A1 (es) Usos terapeuticos de la 4-[2-(4-metilfenilsulfanil)fenil]piperidina
CO6430467A2 (es) Péptidos útiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosméticas o farmacéuticas
ECSP077185A (es) Derivados de piridina
DK2368887T3 (da) 1, 2, 3-triazolderivater til anvendelse som stearoyl-coa desaturase-inhibitorer
CR10963A (es) Compuestos de 2-amino pirimidina
CL2012000457A1 (es) Composicion farmaceutica oral que comprende el compuesto 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]piperazina y sus sales, en donde dicha composicion esta adaptada de manera que dicho compuesto no es liberado en el estomago; y su uso para el tratamiento de trastornos del animo, de ansiedad, de panico, entre otras enfermedades.

Legal Events

Date Code Title Description
FB Suspension of granting procedure